IDEC 106-03--PHASE I/II CLINICAL TRIAL TO EVALUATE IDEC-Y2B8

IDEC 106-03--评估 IDEC-Y2B8 的 I/II 期临床试验

• 批准号: 6245190
• 负责人: Leo I. Gordon
• 金额: $ 1.2万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-15 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245190
• 关键词: B lymphocyte; CD antigens; clinical research; clinical trial phase I; human subject; immunotherapy; monoclonal antibody

IDEC-Y2B8 (IDEC-103) is a murine IgG1 kappa monoclonal antibody and IDEC- C2B8 (IDEC-102) is a chimeric IgG1 kappa monoclonal antibody, with mouse variable and human constant regions. Both antibodies recognize and show specificity for the CD20 antigen expressed on normal B cells and most malignant B-cell lymphomas. High-dose safety studies in cynomolgus monkeys have revealed no adverse clinical events with either antibody, and there were no significant abnormalities on laboratory tests or on histopathology. In vitro mechanism of action studies have demonstrated that IDEC-C2B8 binds human complement and lyses lymphoid B-cell lines. Additionally, it has significant activity in assays for antibody- dependent cellular cytotoxicity. As predicted, the biologic effect of these antibodies is manifested by B-cell depletion in peripheral blood, lymph nodes and bone marrow. In separate studies, several weeks after seven q.o.d. doses of IDEC-Y2B8, and 3 weeks after four weekly doses of IDEC-C2B8, a significant decrease of B cells in bone marrow was observed. Recovery of the B cells in the peripheral blood (to > 75% of baseline) usually occurred within 38 days and 60 days following the last dose of IDEC-Y2B8 and IDEC-C2B8, respectively.

IDEC- y2b8 （IDEC-103）是一种小鼠IgG1 kappa单克隆抗体